Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients with Early Diffuse Cutaneous Systemic Sclerosis

Arthritis and Rheumatology

Volumn 68, Issue 4, 2016, Pages 993-1003

  Domsic, Robyn T ^a   Nihtyanova, Svetlana I ^b   Wisniewski, Stephen R ^a   Fine, Michael J ^a   Lucas, Mary ^a   Kwoh, C Kent ^c   Denton, Christopher P ^b   Medsger, Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ANTIBODY; RNA POLYMERASE III ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; DNA DIRECTED RNA POLYMERASE III;

ADULT; AGE; ANEMIA; ARTICLE; COHORT ANALYSIS; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE DURATION; EXTERNAL VALIDITY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MODEL DERIVATION; MODEL VALIDATION; MORTALITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SKINFOLD THICKNESS; STRATIFIED SAMPLE; SYSTEMIC SCLEROSIS; UNITED KINGDOM; DECISION SUPPORT SYSTEM; DIFFUSE SCLERODERMA; GASTROINTESTINAL DISEASES; GREAT BRITAIN; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; UNITED STATES; VALIDATION STUDY;

ADULT; ANEMIA; AUTOANTIBODIES; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA POLYMERASE III; SCLERODERMA, DIFFUSE; SEX FACTORS; UNITED STATES;

EID: 84962073214     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39490     Document Type: Article

References (40)

1. Bryan C, Howard Y, Brennan P, Black C, Silman A., Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35: 1122-6.
2. Barnett AJ, Miller MH, Littlejohn GO., A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 276-83.
3. Bennett R, Bluestone R, Holt PJ, Bywaters EG., Survival in scleroderma. Ann Rheum Dis 1971; 30: 581-8.
4. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, et al., Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
5. Farmer RG, Gifford RW Jr, Hines EA Jr., Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma: a study of 271 cases. Circulation 1960; 21: 1088-95.
6. Ferri C, Valantini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G., Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
7. Hesselstrand R, Scheja A, Akesson A., Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
8. Nagy Z, Czirjak L., Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16: 454-60.
9. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al., Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-35.
10. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al., Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-167.
11. Tuffanelli DL, Winkelmann RK., Diffuse systemic scleroderma: a comparison with acrosclerosis. Ann Intern Med 1962; 57: 198-203.
12. Wynn J, Fineberg N, Matzler L, Cortada X, Armstrong W, Dillon JC, et al., Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123-7.
13. Silver RM, Medsger TA Jr, Bolster MB., Systemic sclerosis and scleroderma variants: clinical aspects. In:, Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1633-80.
14. Beretta L, Santaniello A, Cappiello F, Chawla NV, Vonk MC, Carreira PE, et al., Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. Clin Exp Rheumatol 2010; 28 Suppl 58: S18-27.
15. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al., Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788-92.
16. Altman RD, Medsger TA Jr, Bloch DA, Michel BA., Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
17. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas N, Michet CJ, et al., Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
18. Jacobsen S, Halberg P, Ullman S., Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-5.
19. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al., Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 139-48.
20. Mayes MD., Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
21. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencvelli W., Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 Suppl 29: S42-6.
22. Medsger TA Jr, Masi AT., Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26: 647-60.
23. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Viella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, et al., Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42: 71-5.
24. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al., Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
25. Assassi S, del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, et al., Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009; 61: 1403-11.
26. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al., Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-6.
27. Domsic RT, Rodriquez-Reyna T, Lucas M, Fertig N, Medsger TA Jr., Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70: 104-9.
28. Mihai C, Landewe R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, et al., Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 2015. E-pub ahead of print.
29. Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K, et al, and the Scleroderma Research Committee Japan. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). J Dermatol 1996; 23: 677-82.
30. Eason RJ, Tan PL, Gow PJ., Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 1981; 11: 657-62.
31. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, et al., Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40: 734-42.
32. Laupacis A, Sekar N, Stiell IG., Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA 1997; 277: 488-94.
33. Hanley JA, McNeil BJ., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
34. Krishnan E, Furst DE., Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20: 855-61.
35. Silman AJ., Scleroderma and survival. Ann Rheum Dis 1991; 50: 267-9.
36. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
37. Van Laar JM, Farge D, Sont JK, Narashi K, Marjanovic Z, Larghero J, et al., Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8.
38. Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M, Kwoh CK, et al., Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2014; 66: 1616-24.
39. Dore A, Lucas M, Ivanco D, Medsger TA Jr, Domsic RT., Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) 2013; 65: 1385-9.
40. Maurer B, Graf N, Michel BA, Muller-Ladner U, Czirjak L, Denton CP, et al., Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124-31.